Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme's Wills Hughes-Wilson switches to Sobi

This article was originally published in Scrip

Executive Summary

Wills Hughes-Wilson has joined Swedish Orphan Biovitrum as vice-president of government affairs and policy reporting to Sobi CEO Geoffrey McDonough. Ms Hughes-Wilson previously served at Genzyme since 2005, most recently as vice-president of health/market access policy, Europe. Prior to Genzyme she was executive director of Emerging Biopharmaceutical Enterprises, a specialised group of EFPIA representing biotech companies in Europe.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016111

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel